NMD4C Launch Canadian Neuromuscular Clinical Trial Network
The Neuromuscular Disease Network for Canada is thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work. Led by investigators Dr. Craig Campbell, Dr. Jean Mah, and Dr. Kerri Schellenberg, the CTN will work towards increasing the number of neuromuscular clinical trials conducted in Canada, enhancing Canadian neuromuscular trial capacity, and supporting a cohesive network of clinician researchers and their teams.
Increasing the number of neuromuscular clinical trials conducted in Canada
The CTN will facilitate connections between industry and clinical sites to support the activation of new clinical trials or the opening of new clinical trial sites. We will deliver information about upcoming neuromuscular trial opportunities and offer information on existing trials available and implement strategic promotion to increase international visibility of the benefits of conducting neuromuscular clinical trials in Canada.
Enhancing trial capacity
The CTN will offer education and training programs to clinicians and their teams to improve clinical trial execution, connect with existing patient organizations to increase opportunities for patients to participate in neuromuscular clinical trials, and gather patient feedback from patient organizations and clinical sites to advance the development of patient-centric clinical trials.
Supporting a network of clinician researchers and their teams
The CTN will facilitate peer-to-peer mentorship opportunities among trialists specializing in neuromuscular clinical trials, coordinate a pan-Canadian hub for trialists and their teams to discuss clinical trial experiences, and launch a Canada-wide community of practice program for clinical trial coordinators overseeing neuromuscular clinical trials.
The CTN leadership group will be supported by Maria Masnata, our new clinical trials and community of practice manager. Learn more about the CTN mission and objectives, or contact Maria Masnata for more information!
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.